Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$69.00 USD

69.00
3,405,133

-0.70 (-1.00%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $68.91 -0.09 (-0.13%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

CONMED (CNMD) Earnings and Revenues Beat Estimates in Q4

by Zacks Equity Research

CONMED's (CNMD) fourth-quarter earnings gain from higher revenues and strong performance in General Surgery segment. However, high long-term debt remains a concern.

What's in Store for Cardinal Health's (CAH) Q2 Earnings?

by Zacks Equity Research

Cardinal Health (CAH) fiscal second-quarter earnings are likely to reflect better-than-expected performance at Pharmaceutical and Medical segments.

Quest Diagnostics (DGX) Q4 Earnings Beat, Margins Strong

by Zacks Equity Research

We are upbeat about Quest Diagnostics' (DGX) expanded network access, which assists the company to expedite volume growth in Q4.

Hologic (HOLX) Q1 Earnings Meet, Revenues Beat Estimates

by Zacks Equity Research

Hologic (HOLX) exhibits robust growth in first-quarter fiscal 2020, fueled by strong performance in the majority of its segments.

Illumina (ILMN) Q4 Earnings Beat Estimates, Margins Expand

by Zacks Equity Research

Illumina (ILMN) exhibits robust growth in the fourth quarter of fiscal 2019, fueled by strong performance of the sequencing consumable segment.

Thermo Fisher (TMO) Q4 Earnings Top, Organic Growth Solid

by Zacks Equity Research

We are upbeat that two of Thermo Fisher's (TMO) four business segments deliver strong year-over-year revenue growth in Q4.

AmerisourceBergen (ABC) Q1 Earnings Beat, Revenues Miss

by Zacks Equity Research

AmerisourceBergen's (ABC) Q1 earnings benefit from higher revenues, segmental growth and strong fiscal 2020 outlook.

Cerner (CERN) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Top-line growth and solid show by Population Health, Revenue Cycle and IT Works are likely to have aided Cerner's (CERN) Q4 earnings. However, contraction in gross margin is likely to have been a dampener.

McKesson (MCK) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

McKesson's (MCK) core U.S. Pharmaceutical and Specialty Solutions unit is expected to reflect in fiscal Q3 results.

Varian (VAR) Earnings and Revenues Miss Estimates in Q1

by Zacks Equity Research

Varian (VAR) gains from core Oncology segment in fiscal Q1.

Align Technology (ALGN) Earnings Beat in Q4, Margins Rise

by Zacks Equity Research

We are upbeat about Align Technology's (ALGN) continued momentum in Invisalign volumes across all geographies during Q4.

Can Solid IC Growth Aid Boston Scientific (BSX) Q4 Earnings?

by Zacks Equity Research

Banking on an innovative portfolio across structural heart and coronary therapies, Boston Scientific's (BSX) IC business is expected to have registered strong sales in Q4.

Stryker (SYK) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Stryker's (SYK) fourth-quarter earnings gain from higher revenues, solid segmental performance and strong organic growth across businesses benefit.

What's in the Cards for Zimmer Biomet (ZBH) in Q4 Earnings?

by Zacks Equity Research

Gains from developments in business segments are likely to get reflected in Zimmer Biomet's (ZBH) revenue results for the fourth quarter and 2019.

Accuray (ARAY) Q2 Earnings Top Estimates, Gross Orders Fall

by Zacks Equity Research

Service revenues drive Accuray's (ARAY) Q2 results, gross margin expands.

PerkinElmer (PKI) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

PerkinElmer's (PKI) Q4 earnings benefits from higher revenues and growth in DAS and Diagnostics segments. However, forex remains a woe.

Baxter (BAX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Higher revenues, solid product portfolio and strong performance across six global business units are likely to have benefited Baxter's (BAX) Q4 earnings.

Here's Why You Should Add HealthEquity (HQY) to Portfolio Now

by Zacks Equity Research

Solid prospects in the HSA industry consistently drive HealthEquity (HQY).

DexCom (DXCM) Gains As Market Dips: What You Should Know

by Zacks Equity Research

DexCom (DXCM) closed at $235.45 in the latest trading session, marking a +0.65% move from the prior day.

Hill-Rom's (HRC) Q1 Earnings Top Estimates, Revenues In Line

by Zacks Equity Research

Sales in Hill-Rom's (HRC) Surgical Solutions suffer a massive setback, thanks to the divestiture of surgical consumables.

What's in Store for Thermo Fisher (TMO) in Q4 Earnings?

by Zacks Equity Research

Strength in segments is expected to get reflected in Thermo Fisher's (TMO) fourth-quarter and 2019 top-line numbers.

Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (DXCM) Outperforming Other Medical Stocks This Year?

Can Critical Care Aid Edwards Lifesciences (EW) Q4 Earnings?

by Zacks Equity Research

Robust customer adoption of the HemoSphere all-in-one monitoring platform is likely to have driven Edwards Lifesciences' (EW) Q4 revenues.

Can Sequencing Products Aid Illumina (ILMN) in Q4 Earnings?

by Zacks Equity Research

Illumina (ILMN) is upbeat about fourth-quarter and fiscal 2019 results after a strong third-quarter performance.

What's in Store for AmerisourceBergen (ABC) in Q1 Earnings?

by Zacks Equity Research

AmerisourceBergen's (ABC) Q1 earnings are likely to reflect the better-than-expected performance at Pharmaceutical Distribution and higher revenues.